FDA Approves ETHOSUXIMIDE — Chartwell Governmental & Specialty RX, LLC.

The FDA has granted approval to Chartwell Governmental & Specialty RX, LLC for the generic version of ETHOSUXIMIDE, which is poised to intensify market competition for the oral medication used to treat absence seizures. This entry is expected to lower retail costs and pressure existing branded players to retrench margins in the antiseizure market portfolio.